Suppr超能文献

免疫细胞疗法的新兴领域。

The Emerging Landscape of Immune Cell Therapies.

机构信息

Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.

Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.

出版信息

Cell. 2020 Apr 2;181(1):46-62. doi: 10.1016/j.cell.2020.03.001.

Abstract

Cell therapies present an entirely new paradigm in drug development. Within this class, immune cell therapies are among the most advanced, having already demonstrated definitive evidence of clinical benefits in cancer and infectious disease. Numerous features distinguish these "living therapies" from traditional medicines, including their ability to expand and contract in proportion to need and to mediate therapeutic benefits for months or years following a single application. Continued advances in fundamental immunology, genetic engineering, gene editing, and synthetic biology exponentially expand opportunities to enhance the sophistication of immune cell therapies, increasing potency and safety and broadening their potential for treatment of disease. This perspective will summarize the current status of immune cell therapies for cancer, infectious disease, and autoimmunity, and discuss advances in cellular engineering to overcome barriers to progress.

摘要

细胞疗法为药物开发带来了全新的模式。在这一类别中,免疫细胞疗法最为先进,已经在癌症和传染病的治疗中证明了明确的临床获益。这些“活疗法”与传统药物有许多不同之处,包括其能够根据需要进行扩张和收缩的能力,以及在单次应用后数月或数年内介导治疗益处的能力。基础免疫学、基因工程、基因编辑和合成生物学的持续进步,使增强免疫细胞疗法的复杂性的机会呈指数级增长,从而提高其效力和安全性,并拓宽其治疗疾病的潜力。本文将总结免疫细胞疗法在癌症、传染病和自身免疫性疾病中的现状,并讨论细胞工程方面的进展,以克服进展的障碍。

相似文献

1
The Emerging Landscape of Immune Cell Therapies.免疫细胞疗法的新兴领域。
Cell. 2020 Apr 2;181(1):46-62. doi: 10.1016/j.cell.2020.03.001.
2
Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials.工程化治疗性T细胞:从合成生物学到临床试验
Annu Rev Pathol. 2017 Jan 24;12:305-330. doi: 10.1146/annurev-pathol-052016-100304. Epub 2016 Dec 5.
3
Synthetic Biology: Immunotherapy by Design.合成生物学:设计免疫疗法。
Annu Rev Biomed Eng. 2018 Jun 4;20:95-118. doi: 10.1146/annurev-bioeng-062117-121147. Epub 2018 Jan 18.
5
Genome edited B cells: a new frontier in immune cell therapies.基因编辑 B 细胞:免疫细胞治疗的新前沿。
Mol Ther. 2021 Nov 3;29(11):3192-3204. doi: 10.1016/j.ymthe.2021.09.019. Epub 2021 Sep 24.
6
Efficient Gene Editing in Primary Human T Cells.高效的基因编辑在原代人 T 细胞中。
Trends Immunol. 2015 Nov;36(11):667-669. doi: 10.1016/j.it.2015.09.001. Epub 2015 Oct 1.
7
Accelerating Diverse Cell-Based Therapies Through Scalable Design.通过可扩展设计加速多样化的基于细胞的疗法。
Annu Rev Chem Biomol Eng. 2024 Jul;15(1):267-292. doi: 10.1146/annurev-chembioeng-100722-121610. Epub 2024 Jul 3.
10
Therapeutic T cell engineering.治疗性T细胞工程
Nature. 2017 May 24;545(7655):423-431. doi: 10.1038/nature22395.

引用本文的文献

本文引用的文献

4
c-Jun overexpression in CAR T cells induces exhaustion resistance.CAR T 细胞中 c-Jun 的过表达诱导衰竭抵抗。
Nature. 2019 Dec;576(7786):293-300. doi: 10.1038/s41586-019-1805-z. Epub 2019 Dec 4.
7
Defining 'T cell exhaustion'.定义“T 细胞耗竭”。
Nat Rev Immunol. 2019 Nov;19(11):665-674. doi: 10.1038/s41577-019-0221-9. Epub 2019 Sep 30.
10
Targeting cardiac fibrosis with engineered T cells.靶向心肌纤维化的工程化 T 细胞。
Nature. 2019 Sep;573(7774):430-433. doi: 10.1038/s41586-019-1546-z. Epub 2019 Sep 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验